Navigation Links
New data showed Actos prevented progression of atherosclerotic plaque volume in patients
Date:3/31/2008

Chicago, IL, March 31, 2008 New data from a clinical trial using intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, ACTOS® (pioglitazone HCl) reduced the atherosclerotic burden in the coronary arteries compared to glimepiride, and prevented progression compared to baseline. These data stem from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial.

The PERISCOPE trial was presented today as a late breaker at the 57th Annual Scientific Session of the American College of Cardiology in Chicago. This trial adds to the body of cardiovascular data for ACTOS. ACTOS studies, conducted over the past 10 years in more than 16,000 patients, including short- and long-term trials, as well as prospective and observational studies, have shown no evidence that ACTOS is associated with an increased risk of heart attack, stroke, or death.

We are pleased with the results of the PERISCOPE, which further expands our cardiovascular data with ACTOS, said David P. Recker, M.D., senior vice president, Clinical Sciences and interim president at Takeda Global Research & Development. While not definitive, data from PERISCOPE combined with results from a previous study, looking at surrogate endpoints, have shown a consistent trend toward decreasing cardiovascular risk by reducing the atherosclerotic burden in people with type 2 diabetes.

PERISCOPE is the first clinical trial to examine the effects of an oral antidiabetic medication on the development of coronary atherosclerosis in patients with type 2 diabetes using IVUS technology. The trial conducted in 97 centers in the U.S., Canada and Latin America with 543 patients, used IVUS imaging of the coronary arteries. The analysis demonstrated a statistically significant difference in percent change in coronary artery atheroma volume in favor of ACTOS treatment compared to glimepiride t
'/>"/>

Contact: Amy Losak
amy.losak@ketchum.com
917-865-6688
Takeda Pharmaceuticals North America
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
2. Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
3. Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
4. New study of Concerta showed significant improvement of ADHD symptom management in adults
5. African Americans at Risk for Low Calcium Intake - New Survey Finds Those Experiencing Symptoms of Lactose Intolerance May be Sidelining Dairy in Their Diets
6. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
7. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
8. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
9. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
10. One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
11. One third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... September 16, 2014 Cliff Lake Dental Care ... Kristaleen is the newest dental hygienist to join Dr. Rauchwarter's ... to working with her and knows she will bring many ... , Kristaleen grew up in River Falls, WI. She ... College in 2003 and practiced dental assisting in the Twin ...
(Date:9/16/2014)... in helping people to reach their fitness and ... wearers improve their wellness by constantly monitoring their ... into companion computer programs and mobile apps. ... for these devices, researchers at the University of ... these activity monitors, such as those made by ...
(Date:9/16/2014)... CO (PRWEB) September 16, 2014 Aspen ... that it has been recognized for its high morale ... Consulting magazine “The Best Small Firms to Work For ... survey annually, with more than 10,000 consultants participating across ... Extensive employee satisfaction surveys were conducted, and firms were ...
(Date:9/16/2014)... September 14, 2014 A new study found ... (SB) stenting of true coronary bifurcation lesions yields ... The DKCRUSH-VI clinical trial is the first study ... Findings were reported today at the 26th annual ... the Cardiovascular Research Foundation (CRF), TCT is the ...
(Date:9/16/2014)... with endocrine therapy and radiation therapy as part ... care for women with hormone-receptor positive (HR+) invasive ... Fox Chase Cancer Center, however, shows that combination ... with the disease. , The results, which ... for Radiation Oncology,s 56th Annual Meeting on Sunday, ...
Breaking Medicine News(10 mins):Health News:Cliff Lake Dental Care Announces Newest Team Member 2Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3
... patients covered by compensation have worse physical and life-quality ... to new research. ,Orthopaedic injury, usually ... form of hospitalisation in Australia, according to the study ... ,,The authors Professor Peter Cameron, Head of ...
... health doctors argue for routine opt-out HIV testing in ... departments and hospital wards. ,In the first article, ... people in the UK with HIV do not know they ... for pregnant women and people attending genitourinary (GUM) clinics. ...
... taken before meals, can improve blood glucose control for people ... with short-acting injected insulin that is taken in addition ... according to a new review of the body of published ... 2 diabetes typically have to take extra insulin at mealtimes ...
... AVGO), a late stage biotechnology company that develops central ... selection of the optimal dose of HD-02, its ... ,This dose was determined in an open-label ... Dr. Diana Rosas of Massachusetts General Hospital (MGH), and ...
... mass displacement of people in sub-Saharan Africa do not necessarily ... refugee agency said on Friday. ,Contradicting a ... the UN High Commissioner for Refugees (UNHCR) said that out ... actually had a lower rate than surrounding host communities. ...
... who was detained for 30 years in his native Cuba, realized ... a ceremony in Miami. ,Now, he says, his ... the former fisherman is convinced he will outlive the ailing Cuban ... far less healthy than I am, he can hardly talk," Temprana ...
Cached Medicine News:Health News:Doctors Call for Opt-out Approach to HIV Testing 2Health News:Inhaled Insulin for Type 2 Diabetes Shows Mixed Results 2Health News:Inhaled Insulin for Type 2 Diabetes Shows Mixed Results 3Health News:Avicena to Advance Huntington's Disease Clinical Program into Phase III 2Health News:No Clear Link Between Conflict, Rape and HIV: UN Study 2Health News:The American Dream Comes True for 105-year-old Cuban 2
(Date:9/16/2014)... , Sept. 16, 2014 Chindex International, ... ) announced that, at a special meeting of stockholders ... merger agreement (the "Merger  Agreement") by and among the ... Acquisition, Inc. ("Merger Sub"). Parent is an affiliate of ... Ms. Roberta Lipson , the CEO of the ...
(Date:9/16/2014)... Research and Markets has announced the addition of the ... offering. Animal vaccines are biological preparations used ... prepared from weakened or dead microbes that can cause a ... animal vaccines are also formulated using a part of a ... These components act as stimulating agents that trigger ...
(Date:9/16/2014)... 16, 2014 QPID Health , a leader ... headquarters in Boston and their first ... be at 175 Franklin Street in Boston ... QPID Health,s new Southern California office ... expansion will help meet the demands of customers nationwide.  Both ...
Breaking Medicine Technology:Chindex Stockholders Approve Merger 2Chindex Stockholders Approve Merger 3Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2
... Switzerland, June 23 Debiopharm Group,(Debiopharm), a Swiss-based global ... of prescription drugs that target unmet medical,needs, announced that ... was launched in Germany in May 2009, by Dr ... on a preliminary basis in,Belgium. The effective commercial launch ...
... --Whole-Genome Searches Are Revealing Secrets of a Childhood Cancer-- , ... The Children,s Hospital of Philadelphia advance the search for genetic ... childhood cancer. , , Originating in the peripheral nervous ... childhood and causes 15 percent of all childhood cancer deaths. ...
Cached Medicine Technology:Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries 2Gene Findings Unlocking Reasons for Neuroblastoma Risk 2Gene Findings Unlocking Reasons for Neuroblastoma Risk 3Gene Findings Unlocking Reasons for Neuroblastoma Risk 4
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Medicine Products: